comment: ftd/tpi bev ftd/tpi provides benefits for metastatic colorectal cancer patients
Published 2 years ago • 66 plays • Length 1:06Download video MP4
Download video MP3
Similar videos
-
6:00
ftd/tpi bev and ftd/tpi provides benefits for metastatic colorectal cancer patients
-
1:09
ftd/tpi and bevacizumab versus ftd/tpi monotherapy in metastatic crc
-
2:52
a phase iii study of bbi-608 and folfiri in patients with metastatic colorectal cancer
-
2:52
metastatic colorectal cancer: trifluridine/tiripacil or regorafenib?
-
8:16
encorafenib & binimetinib cetuximab for untreated braf v600e-mutant metastatic colorectal cancer
-
14:07
strategies in metastatic colorectal cancer
-
2:52
colorectal cancer: patient follow-up with trifluridine/tipiracil
-
1:32
dr. lee on the benefit of cytoreductive surgery in metastatic colorectal cancer
-
4:30
trifluridine/tipiracil in advanced colorectal cancer
-
1:16
enhancing metastatic pmmr colorectal cancer treatments
-
3:21
frontline therapy for stage iv right-sided crc
-
3:53
when you have decided to prescribe trifluridine/tipiracil
-
7:43
practical advice for using trifluridine/tipiracil
-
7:02
setting expectations in third-line colorectal cancer
-
5:18
trifluridine/tipiracil: an emerging strategy for the management of gastrointestinal cancers
-
1:42
the cytokine protein ccl7 promotes bone metastasis from colorectal cancer
-
6:24
mcrc: right-side vs left-side tumors
-
0:30
scott kopetz, md, phd, facp, explains how nivolumab is being incorporated into mcrc treatment
-
0:26
dr. eng: egfr-directed therapy and mutational status